2024, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year.   

 

Top 20 Medical Device Companies of 2024  

Shots:   

• Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received  
• With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in our list, followed by JNJ and Siemens Healthineers with $30.40B and $24.04B respectively   
• PharmaShots brings a concise report on the Top 20 Medical Device Companies Based on 2023 Revenue   

 

Top 20 Nutraceutical Companies of 2024 

Shots: 

• Nutraceuticals offer miraculous health benefits by enhancing body function and assisting in body repair and growth 
• In 2023, the global Nutraceuticals market was valued at $419.93B and is expected to increase from $457.35B in 2024 to $976.74B by 2032 with a CAGR of 9.95 percent. Nestlé ranks first on our list with reported segment revenue of $18.18B, followed by Danone and BASF SE with $9.38B and $7.61B, respectively 
• PharmaShots presents a concise report on the Top 20 Nutraceutical Companies based on the reported nutritional segment revenue of 2023 

 

Top 20 Biopharma Companies of 2024 

Shots: 

• Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic 
• With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of $799.76B by 2030. In 2023, JNJ ranked first in our list with a total reported revenue of $85.16B followed by Roche and Merck & Co. With $69.78B and $60.11B respectively 
• PharmaShots brings a succinct report on the Top 20 Biopharma Companies in 2024 based on their last year's revenue 

 

Top 20 Generic Pharma Companies of 2024 

Shots: 

• Known for delivering the same therapeutic benefits as its brand-name counterpart, it won't be an exaggeration to refer to generic drugs as modern-day advocates for health equity 
• In 2022, the global market size of generic drugs was valued at $411.99B and is envisioned to reach $613.34B by 2030 with a CAGR of 5.10%. Sandoz ranks first in our list with a total of $9.64B generic segment revenue followed by Teva Pharmaceuticals with $8.73B & Sun Pharma with $5.7B respectively 
• PharmaShots brings a succinct report on the Top 20 Generic Pharma Companies based on 2023 revenue 

 

Top 20 Diagnostic Companies of 2024  

Shots:   

• Propelled by unceasing innovations and inch-perfect precision, the diagnostic industry is advancing at an astonishing pace  
• In 2023, the global diagnostic test market size was valued at $210.58B and is envisioned to reach $284.38B by 2033, registering a CAGR of 3.05 percent from 2024 to 2033. Roche reclaims its first position with a revenue of $16.76B, followed by GE Healthcare and Abbott Laboratories with $16.34B and $9.98B, respectively  
• PharmaShots brings a concise report on the top 20 diagnostic companies based on 2023 revenue 

 

J.P. Morgan Special: Deal Maker of the Year 2023 (Part 01) 

Shots: 

• As the year began, PharmaShots was busy analyzing the deals throughout 2023 to prepare a special report, viz. JP Morgan 2024 Special: Deal Maker of the Year 2023 (Part 01) 

• The report features Roche, that signed 26 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases 

• Propelled by the invaluable insights from DealForma, PharmaShots brings an on-demand report on the Dealmaker of the Year 2023 

 

J.P. Morgan Special: Dealmaker of the Year 2023 (Part 02)  

Shots:  

• In the next installment of Dealmaker 2023, we bring an informative report on the Top M&A based on the Deal Value   

• The report revolves around Pfizer, which signed 16 collaborations comprising acquisitions, contract services, development & commercialization, license, R&D, and product purchases that have summed to a total of $63.23B   

• Propelled by the invaluable insights from DealForma, PharmaShots brings an on-demand report on the Dealmaker of the Year 2023    

 

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023) 

Shots:   

• Witness the journey of the biopharma companies over 20 years with this informative and engaging report. The report highlights the development of the biopharma industry and the key factors influencing them  

• In 2023, JNJ reclaims the topmost position in the list from Pfizer with a revenue of $85.16B, showcasing a sharp 10.30 percent vs 2022, followed by Roche & Merck & Co.  

• PharmaShots brings a detailed analysis report on the growth of biopharma companies over 20 years, depicted through an illustrative time-lapse bar chart video   

 

Insights+: The US FDA New Drug Approvals in December 2023  

Shots: 

• The US FDA approved 11 NDAs & 2 BLAs in December 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023 

• In December 2023, the major highlight drugs were Jaypirca (pirtobrutinib) approved for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, and Iwilfin (belzutifan) for the Treatment of Renal Cell Carcinoma 

• PharmaShots has compiled a list of US FDA approved drugs in the month December 2023 

 

Insights+: EMA Marketing Authorization of New Drugs in February 2024 

Shots: 

• The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry 

• In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis 

• PharmaShots has compiled a list of a total of 8 new drugs approved by the EMA in February 2024 

 

Disease of the Month - Duchenne Muscular Dystrophy (DMD) 

Shots:  

• The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved   

• For the April edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Duchenne Muscular Dystrophy, a genetic problem that causes muscles to weaken and atrophy  

• The condition most commonly affects children between 3 and 6 years of age 

 

Know Your Investor (January Edition): RA Capital Management 

Shots:   

• New Year, New Us! Our hand curated “Know Your Investor” reports will now be exploring leading investors of 2023   

• Founded in 2002, RA Capital forged ahead to become a key investor in life science and healthcare companies. In 2023, RA Capital closed 40 major investments in biopharma companies, devices, manufacturing, service offering firms, and diagnostics   

• An illustrative table concludes the report, listing five major investments out of 40. For a complete report reach out to us at connect@pharmashots.com  with the subject line “RA Capital Management Data”  

 

New Drug Designations - February 2024 

Shots: 

• PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, and EC. This month’s report includes designations allotted to 13 small molecules, 20 biologics, and 2 devices  

• SN Bioscience’s SNB-101 received ODD from the US FDA for the treatment of pancreatic cancer based on preclinical results. It has previously received the US FDA’s ODD for treating SCLC in Jul 2023  

• PharmaShots has compiled a list of a total of 33 drugs and 2 devices awarded with designations by multiple regulatory bodies in Feb 2024 

 

Insights+ Key Biosimilars Events of April 2024 

Shots:    

• Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency     

• Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients     

• During April, Samsung Bioepis and Sandoz received the EC’s Marketing Authorization approval for Pyzchiva. Our team at PharmaShots has summarized 8 key events of the biosimilar space of April 2024 

 

PharmaShots' Key Highlights of First Quarter 2024 

Shots: 

• The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3B 

• This quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS' P-III results for Krazati  

• Our team at PharmaShots has summarized and compiled the insights of Q1'2024 

 

Redefining the Frontiers of Healthcare with IoMT 

Shots:  

• The Internet of Medical Things, aka IoT in Healthcare, has put a profound impact on healthcare services and practices globally   

• In 2022, the global IoMT market was valued at $144.23B. The numbers are envisioned to reach $636.89B by 2030 with a CAGR of 20.4 percent   

• With this, article let’s navigate the IoMT, its importance in healthcare, its classification based on its wide range of applications, and the challenges   

 

Targeted Therapy in Oncology 

Shots:  

• The oncology domain accounts for more than 50% of ongoing clinical trials. The global oncology drug market was valued at $185B in 2022 and is predicted to reach $205B by 2030 with a 13% CAGR   

• Targeted therapy targets specific genes and proteins to prevent them from growing and spreading. In 2022, the market size of Targeted Therapy accounted for $70B and is expected to hit $137.05B by 2032 with a 7% CAGR   

• PharmaShots brings an illuminating guide to Targeted Therapy in Oncology with this informative article   

 

Rashmi Gurnani from AKT Health Analytics in a Riveting Dialogue Exchange with PharmaShots 

Shots: 

• Rashmi Gurnani, CEO of AKT Health Analytics, sheds light on AKT’s distributor partnership with Certara 

• Rashmi discusses AKT’s role in assisting the US clients with Japan’s PMDA approval 

• While outlining the innovative services that the company offers, Rashmi emphasizes the company’s upcoming platform IMPAKT Health, an IoT AI-enabled DLA capture platform 

 

David A. Dodd, Chairman President and CEO of GeoVax Labs Inc. in a riveting conversation with PharmaShots 

Shots: 

• David A. Dodd CEO of GeoVax sheds light on the company’s recent partnership with Allucent to conduct a P-IIb clinical study of GEO-CM04S1, a dual antigen next-gen COVID-19 vaccine  

• BARDA came into aid to fund this project through Project NextGen, a 5B initiative by HHS  

• The P-IIb study will evaluate 10000 participants to evaluate the relative efficacy of GEO-CM04S1 in comparison to FDA-approved COVID-19 vaccines to prevent symptomatic SARS-COV-2 infection  

 

Jonathan Usuka Chief Business Officer at Sapient, in a Stimulating Conversation with PharmaShots 

Shots: 

• Jonathan Usuka, Chief Business Officer at Sapient, discusses Sapient’s high throughput proteomics and metabolomics capabilities  

• Using these capabilities Sapient aims to generate multi-omics data and analytical power to transcend the genome and achieve robust biological discoveries in expediting clinical studies  

• Using Sapient’s real-world data asset, Jonathan manages commercial collaborations, strategic partnerships, and client service innovation  

 

Jed Litwiniuk & Uwe Tigör from Auxilius Pharma in a Riveting Dialogue Exchange with PharmaShots 

Shots: 

• PharmaShots welcomes Jed Litwiniuk and Uwe Tigör from Auxilius Pharma in the fifth episode of CXO Talks 

• Jed and Uwe highlight the company’s recent presentation on P-1a results of AUX-001 at the European Society of Cardiology  

• The duo discusses AUX-002 and AUX-003, currently in formulation 

 

Nick Kadysh the Founding CEO & President at PharmAla Biotech, in an Illuminating Dialogue Exchange with PharmaShots 

Shots: 

• Nick, Founding CEO & President of PharmAla Biotech shares the exciting journey of PharmAla becoming an MDMA-focused company 

• PharmAla recently joint ventured with Vitura Health to form Cortexa, aiming to make it a leading MDMA and Psilocybin supplier in the Australian market 

• Nick discusses the recent patent allowance for ALA-002 by the USPTO 

  

 

Thermo Fisher Scientific, in an Enlightening Conversation with PharmaShots 

Shots:   

• Advances in Cryo-EM help better understand biological molecules and complexes at atomic resolution. Thermo Fisher Scientific’s recently launched Glacios 2 Cryo-TEM with E-CFEG offers promising potential in reducing the workflow complexities with automation  

• Today, we have Jeffrey Lengyel Director of Life Sciences, Cryo-EM, at Thermo Fisher Scientific shedding light on Glacios 2 Cryo-TEM with E-CFEG  

• Jeffrey highlights the significance of the update to Glacios 2 Cryo-TEM, a 200 kV microscope that now can generate near-atomic resolution at <2A of small molecules and proteins 

 

Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots 

Shots: 

• Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseases 

• ARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) 

• Angela sheds light on the company’s portfolio of neurodegenerative disorder 

 

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services 

Shots:  

• Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots  

• Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome  

• While highlighting Sapient’s multi-omics pipeline for biocomputational analysis, Mo sheds light on the Sapient Human Biology Database that comprises multi-omics data collected in over 100,000 human biosamples 

 

Enhancing Neurodegenerative Care: Stella Sarraf from Spinogenix in an Enlightening Dialogue Exchange with PharmaShots 

Shots:  

• With a broad portfolio of candidates in ALS, Alzheimer’s disease, Schizophrenia, and Fragile X Syndrome, Spinogenix initiated the P-II study evaluating SPG302 for the treatment of patients with Alzheimer’s disease  

• SPG302, a synaptic regenerative therapy, is aimed to provide an effective and patient-friendly solution as a daily pill for ALS and Alzheimer’s disease  

• Today at PharmaShots, we have Stella Sarraf, CEO, Founder & Director at Spinogenix, shedding light on the study design from the P-II trial of SPG302 

 

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots 

Shots:    

• Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL   

• Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with PharmaShots. TEPKINLY is now available in the European Union (EU), as well as in Liechtenstein, Norway, and Iceland   

• While sharing the highlights from the EPCORE™ NHL-1 P-I/II study, Julie and Michael talk about the conditional approval of TEPKINLY and discuss in great length the prospect of evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies   

 

Novo Holdings to Acquire Catalent for ~$16.5B 

Shots: 

• Novo Holdings to acquire Catalent in an all-cash transaction with a total enterprise value of ~$16.5B 

• As a part of the transaction, Catalent common stockholders will receive $63.50/share in cash, reflecting a premium of approximately 47.5% over the 60-day volume-weighted average price as of February 2, 2024 

• Moreover, out of 50 Catalent global sites, Novo Holdings plans to sell 3 fill-finish sites (Italy, USA, Belgium) & related assets acquired from Catalent to Novo Nordisk 

 

Vertex to Acquire Alpine Immune Sciences for ~$4.9B 

Shots: 

• Vertex has signed a definitive agreement to acquire Alpine Immune Sciences for $65 per unit making it a total of ~$4.9B in cash. The transaction will conclude in the Q2’24 

• The acquisition will add Alpine’s povetacicept (ALPN-303) to the company’s portfolio, which demonstrated effectiveness in the P-II study of IgA nephropathy. The drug’s P-III clinical evaluation in anticipated in H2’24 

• Povetacicept is a dual BAFF (B cell activating factor) & APRIL (a proliferation inducing ligand) cytokines antagonist which are responsible for the pathogenesis of various autoimmune diseases by activating, differentiating & sustaining B cells, T cells & innate immune cells 

 

Gilead Sciences to Acquire CymaBay Therapeutics for ~$4.3B 

Shots: 

• The acquisition was made as a step to expand its existing liver portfolio by the addition of CymaBay’s Seladelpar, a treatment for PBC including pruritus 

• Gilead will commence a tender offer to acquire all outstanding shares of CymaBay’s common stock for $32.5/share in cash at a 27% 1-day premium adding to an equity value of $4.3B following the completion of which, Gilead will acquire all the remaining shares not tendered in the offer through a second step merger at the same price 

• Seladelpar (oral selective PPARδ agonist) was evaluated in a P-III (RESPONSE) trial based on the results of which the US FDA accepted CymaBay’s NDA, granted priority review & assigned a PDUFA date of Aug 14, 2024 

 

Carlyle to Acquire Baxter International’s Vantive Kidney Care Segment for $3.8B 

Shots: 

• Baxter International and Carlyle have entered into a definitive agreement as per which Carlyle will acquire Baxter's Vantive Kidney Care segment for an aggregate of $3.8B. The transaction is anticipated to conclude in H2’24 or H1’25 

• As per the agreement, Baxter will get ~$3.5B in cash from the deal, estimated ~$3B after-tax proceeds, and remaining will be used for working capital and debt adjustment 

• Vantive Kidney Care segment provides products and services for peritoneal dialysis, hemodialysis and organ support therapies such as continuous renal replacement therapy (CRRT) 

 

Eli Lilly to Acquire Morphic Holdings for an Aggregate of ~$3.2B 

Shots: 

• Eli Lilly has entered into a definitive agreement to acquire Morphic Holding to strengthen its immunology portfolio by adding oral integrin therapies 

• The company will buy Morphic’s outstanding shares for $57 per share in cash making it a total deal value of ~$3.2B. The transaction is anticipated to conclude in Q3’24, pending customary closing conditions 

• The acquisition will add Morphic’s MORF-057 (α4β7 integrin inhibitor) being assessed under three P-II trials (2 for ulcerative colitis & 1 for Crohn's disease) and various preclinical candidates for treating autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases & cancer to Lilly’s portfolio 

 

Novartis Reports Acquisition of MorphoSys for ~$2.9B 

Shots: 

• Novartis has signed an agreement to acquire MorphoSys as a strategic step to enhance its oncology and hematology pipeline by owning programs incl. pelabresib, being evaluated in the P-II study as a 2L treatment for essential thrombocythemia & tulmimetostat, targeting EZH1 and EZH2 proteins, being investigated for solid tumors or lymphomas 

• Novartis will take over all MorphoSys’ no-par value bearer shares for ~$73 each, making it a total of ~$2.9B in cash 

• The transaction, to be concluded in H1'24, has certain closing conditions with Novartis seeking a minimum 65% acceptance of MorphoSys’ outstanding shares and regulatory approvals. MorphoSys will function as an independent company until the closure 

 

AstraZeneca Acquires Fusion Pharmaceuticals for ~$2.4B to Development Radioconjugates for Cancer Treatment 

Shots: 

• AstraZeneca has signed a definitive agreement to acquire Fusion to expedite the development of radioconjugates for cancer treatment 

• AstraZeneca will acquire all of Fusion’s outstanding shares for $21.00/unit in cash making it a total of ~$2B & a non-transferable CVR of $3.00/unit in cash on reaching a specific regulatory milestone, making a total deal value of ~$2.4B. It will further acquire its cash, cash equivalents & short-term investments for $234M as of Dec 31, 2023 

• The acquisition adds Fusion’s RC pipeline incl. FPI-2265, under P-II trial for mCRPC, to AstraZeneca’s portfolio as well as new expertise in R&D plus manufacturing & supply chain capabilities in Ac-based RCs along with strengthening its presence across Canada 

 

ONO Pharmaceutical Reports Acquisition of Deciphera Pharmaceuticals for $2.4B 

Shots: 

• ONO has signed a definitive merger agreement with Deciphera to enhance its oncology portfolio and expand its presence across the US & the EU, strengthening kinase drug discovery research 

• Under the agreement, ONO will acquire Deciphera’s outstanding shares for $25.60 per unit in cash followed by merging Deciphera with its subsidiary, totaling $2.4B in equity value. The transaction will conclude in Q3’24 

• The acquisition will further add Qinlock (switch-control inhibitor) to treat 4L gastrointestinal stromal tumor (approved in the US & 40 other regions), its drug candidates incl. vimseltinib & DCC-3116 (an ULK inhibitor) along with additional oncology candidates to ONO’s portfolio 

 

Basilea Pharmaceutica Acquires Spexis’ Preclinical Antibiotics Program for $2.34M 

Shots: 

• Basilea Pharmaceutica and Spexis have signed an asset purchase agreement for preclinical antibiotics program focusing on gram-negative bacteria, incl. novel multidrug-resistant strains 

• As per the agreement, Basilea acquires all program compounds, know-how, and intellectual property from Spexis for a total payment of $2.34M (CHF 2M) which includes an up front payment, a transfer-related payment, and a potential final milestone payment linked to near-term external funding for the program's development 

• Additionally, Basilea also takes over Spexis' rights and obligations, incl. potential low single-digit percentage royalties on sales through licensing agreements 

 

Sanofi Acquires Inhibrx for ~$2.2B, Adding INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD) to its Pipeline 

Shots: 

• Sanofi signed a definitive agreement to acquire Inhibrx following the spin-off of non-INBRX-101 assets into Inhibrx Biosciences. The transaction is expected to close by Q2’24 

• As per the agreement, Sanofi will acquire all outstanding shares of Inhibrx for $30.0 per share in cash adding to an equity value of ~$1.7B, will pay Inhibrx’s outstanding third-party debt & will retain 8% equity in New Inhibrx through $200M investment  

• Inhibrx’s shareholders will receive one non-transferable CVR per Inhibrx share entitling its holders to receive a deferred cash payment of $5/share CVR for a total CVR value of $800M (upon achieving regulatory milestones). The shareholders will also receive 0.25 share in New Inhibrx per Inhibrix share 

 

Related Post: Most Viewed Articles of 2023